The key role that IL-1β plays in gout and pseudo-gout was further confirmed by the effectiveness of blocking agents to IL-1 in that it reduced acute attacks, initially observed after the administration of IL-1Ra anakinra, and then to the anti-IL-1β monoclonal antibody canakinumab (So et al., 2007; Schlesinger et al., 2012; Punzi and So, 2013). This evidence concerns the gene IL1A and gout.